Heart and Vascular Care

Heart and Vascular Care

The following list contains clinical studies in which the OSF HealthCare Cardiovascular Institute is enrolling patients.

For questions or to enroll, please contact our research staff at (309) 589-1930 in the Peoria area and (815) 395-9181 in Rockford.

Currently Enrolling - Peoria Area

  • UPSTREAM - Utilization of Ticagrelor in the Upstream Setting for Non-ST-Segment Elevation Acute Coronary Syndrome: An ED-Based Clinical Registry

  • Summary: An ED-Based clinical registry evaluating the utilization of Ticagrelor in the upstream setting for Non-ST-Segment Elevation Acute Coronary Syndrome.

    Investigator: Sudhir Mungee

    Location: OSF HealthCare Cardiovascular Institute, Peoria, Illinois

    ClinicalTrials.gov: NCT02271022

    Contact: Stephanie Hillis, (309) 589-1934, stephanie.j.hillis@osfhealthcare.org

  • PRESERVED HF - Effects of dapagliflozin on biomarkers, symptoms and functional status in patients with Type 2 diabetes or pre-diabetes, and PRESERVED ejection fraction Heart Failure

  • Summary: A study to evaluate the effects of Dapagliflozin on biomarkers, symptoms and functional status in patients with Type II Diabetes or pre-diabetes, and preserved Ejection Fraction Heart Failure.

    Investigator: Barry Clemson

    Location: OSF HealthCare Cardiovascular Institute, Peoria, Illinois

    ClinicalTrials.gov: NCT03030235

    Contact: Rita Klundt, (309) 589-1937, rita.j.klundt@osfhealthcare.org

  • VICTORIA - A Randomized Parallel-Group, Placebo-Controlled, Double-Blind, Event-Driven, Multi-Center Pivotal Phase III Clinical Outcome Trial of Efficacy and Safety of the Oral sGC Stimulator Vericiguat in Subjects With Heart Failure With Reduced Ejection Fraction (HFrEF) – VerICiguaT GlObal Study in Subjects With Heart Failure With Reduced EjectIon FrAction

  • Summary: A study to evaluate the efficacy and safety of the oral sGC stimulator Vericiguat in subjects with Heart Failure with reduced Ejection Fraction.

    Investigator: Barry Clemson

    Location: OSF HealthCare Cardiovascular Institute, Peoria, Illinois

    ClinicalTrials.gov: NCT02861534

    Contact: Stephanie Hillis, (309) 589-1934, stephanie.j.hillis@osfhealthcare.org

Currently Enrolling - Rockford Area

Peripheral Artery Disease (PAD)

  • GORE ISR 14-04 - Post-Approval Study of the GORE® VIABAHN® Endoprosthesis for the Treatment of In-Stent Restenosis (ISR) in the Superficial Femoral Artery (SFA)

  • Summary: A Clinical trial for patients who have already had stents in the legs and are experiencing reoccurring symptoms of PAD.

    Investigator: Asad Sheikh

    Location: OSF HealthCare Cardiovascular Institute, Rockford, Illinois

    ClinicalTrials.gov: NCT02542267

    Contact: Joanne Carner, (815) 395-9181, joanne.e.carner@osfhealthcare.org

  • PRESERVE II - Clinical Study to Evaluate the Safety and Effectiveness of the Zenith®Branch Endovascular Graft-Ililac Bifurcation (PRESERVE-Zenith®Iliac Branch)

  • Summary: A Clinical trial for patients with an iliac aneurysm needing treatment.

    Investigator: David Cable

    Location: OSF HealthCare Cardiovascular Institute, Rockford, Illinois

    ClinicalTrials.gov: NCT02571907

    Contact: Lindsey Tompkins, (815) 395-9181, lindsey.a.tompkins@osfhealthcare.org

Follow-Up Only - Peoria Area

  • IMPERIAL - A randomIzed trial coMParing the ELUVIA™ dRug-elutIng stent versus Zilver® PTX® stent for treatment of superficiAL femoral and/or proximal popliteal arteries

  • Summary: A randomized trial comparing the ELUVIA™ drug-elutIng stent versus Zilver® PTX® stent for treatment of superficial femoral and/or proximal popliteal arteries.

    Investigator: John Rashid

    Location: OSF HealthCare Cardiovascular Institute, Peoria, Illinois

    Contact: Rita Klundt, (309) 589-1937, rita.j.klundt@osfhealthcare.org

  • REVEAL - Randomized EValuation of the Effects of Anacetrapib through Lipid-modification: A large-scale, randomized placebo-controlled trial of the clinical effects of anacetrapib among people with established vascular disease

  • Summary: A trial to evaluate the effects of anacetrapib among people with established vascular disease.

    Investigator: Tinoy Kizhakekuttu

    Location: OSF HealthCare Cardiovascular Institute, Peoria, Illinois

    Contact: Rita Klundt, (309 589-1937, rita.j.klundt@osfhealthcare.org

  • ABSORB III - Randomized Controlled Trial - A Clinical Evaluation of Absorb™ BVS, the Everolimus Eluting Bioresorbable Vascular Scaffold in the Treatment of Subjects with de novo Native Coronary Artery Lesions

  • Summary: A randomized, controlled trial to Evaluate the Absorb™ BVS, the Everolimus Eluting Bioresorbable Vascular Scaffold in the treatment of subjects with de novo native coronary artery lesions.

    Investigator: Sudhir Mungee

    Location: OSF HealthCare Cardiovascular Institute, Peoria, Illinois

    Contact: Stephanie Hillis, (309) 589-1934, stephanie.j.hillis@osfhealthcare.org

  • EXCEL - Evaluation of XIENCE versus Coronary Artery Bypass Surgery for Effectiveness of Left Main Revascularization

  • Summary: Evaluation of XIENCE versus Coronary Artery Bypass Surgery for effectiveness of left main revascularization.

    Investigator: John Rashid

    Location: OSF HealthCare Cardiovascular Institute, Peoria, Illinois

    Contact: Rita Klundt, (309) 589-1937, rita.j.klundt@osfhealthcare.org

  • OVATION PAS - A PMA Post-Approval Study to Evaluate the Long-Term Safety and Effectiveness of the Ovation™/Ovation Prime™ Abdominal Stent Graft System

  • Summary: A post-PMA approval, prospective, consecutively enrolling, nonrandomized multi-center clinical study to evaluate the safety and effectiveness of the Ovation/Ovation Prime Abdominal Stent Graft System through five years of implantation.

    Investigator: Ryan Nolte

    Location: OSF HealthCare Cardiovascular Institute, Peoria, Illinois

    Contact: Stephanie Hillis, (309) 589-1934, stephanie.j.hillis@osfhealthcare.org

  • QUAD PAS - Quadripolar Pacing Post Approval Study

  • Summary: A post approval study evaluating the acute and chronic performance of a Quadripolar CRT-D device system in a patient population indicated for cardiac resynchronization therapy.

    Investigator: Joseph Sarmiento

    Location: OSF HealthCare Cardiovascular Institute, Peoria, Illinois

    Contact: Stephanie Hillis, (309) 589-1934, stephanie.j.hillis@osfhealthcare.org

  • SJM CLAS - St. Jude Medical Cardiac Lead Assessment Study

  • Summary: A post market study to determine the prevalence and incidence of externalized conductors and other visual lead anomalies (as evidenced by imaging) and the risk of progression to electrical dysfunction in a large series of ICD/ CRT-D/CRT-P devices containing one or more of the following SJM leads: Riata leads, Riata ST silicone leads, Durata leads, QuickSite/QuickFlex CRT leads.

    Investigator: Joseph Sarmiento

    Location: OSF HealthCare Cardiovascular Institute, Peoria, Illinois

    Contact: Rita Klundt, (309) 589-1937, rita.j.klundt@osfhealthcare.org

  • THEMIS - A Multinational, Randomized, Double-Blind, Placebo Controlled Trial to Evaluate the Effect of Ticagrelor twice daily on the Incidence of Cardiovascular Death, Myocardial Infarction or Stroke in Patients with Type 2 Diabetes Mellitus

  • Summary: A Randomized trial to evaluate the effect of Ticagrelor twice daily on the incidence of cardiovascular death, myocardial infarction or stroke in Patients with Type 2 Diabetes Mellitus.

    Investigator: Tinoy Kizhakekuttu

    Location: OSF HealthCare Cardiovascular Institute, Peoria, Illinois

    Contact: Rita Klundt, (309) 589-1937, rita.j.klundt@osfhealthcare.org